CARB-X funds Recida Therapeutics to develop a new class of antibiotics to treat deadly infections caused by Gram negative superbugs

CARB-X, a Boston University global partnership, is awarding Recida Therapeutics of Menlo Park, CA, USA, up to $4.4 million in non-dilutive funding to develop a novel antibiotic to treat serious infections caused by Gram-negative bacteria.

Article: CARB-X